Replies to post #116251 on Biotech Values

[genisi]

EASL - first SVR data for mericitabine (a.k.a RG7128 ) interim analysis from the Jump-C phase 2b study. Note the high relapse rate

http://www.natap.org/2011/EASL/EASL_30.htm